瑞士制药巨头 诺华 （Novartis）周二表示，已同意以至多30.8亿美元的价格收购美国私人控股的临床阶段生物制药公司Anthos Therapeutics，以扩大其心血管药物管线。

瑞士药厂诺华制药 (Novartis)同意以最多31亿美元收购生物制药公司Anthos Therapeutics，後者由黑石集团 (BX.US) 控股的药物开发公司所拥有。

By Ludwig Burger and Ariane Luthi (Reuters) -Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a ...

Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a biopharma firm majority-owned by ...

Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement ...

Novartis (NVS) has sealed a $3.1 billion deal to acquire clinical-stage biopharmaceutical company Anthos Therapeutics. The ...

Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 ...

The acquisition of Anthos Therapeutics could be worth up to $3.1 billion and returns to Novartis a blood thinner it licensed ...

Novartis has agreed to acquire Boston-based clinical-stage biopharmaceutical company Anthos Therapeutics for an upfront ...

Novartis is paying $925 million upfront to acquire Anthos Therapeutics, whose launch the pharma backed in February 2019.

Novartis has agreed to buy Anthos Therapeutics from private equity firm Blackstone for $3.1 billion, adding a drug in ...

Novartis (NVS) announced that it has entered into an agreement to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, ...